AMERIPRISE FINANCIAL INC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 323 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.

Quarter-by-quarter ownership
AMERIPRISE FINANCIAL INC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$17,080,856
+1.1%
447,143
-4.5%
0.01%
+20.0%
Q2 2023$16,890,025
-14.8%
468,257
-9.8%
0.01%
-16.7%
Q1 2023$19,815,600
-33.8%
518,869
-1.4%
0.01%
-40.0%
Q4 2022$29,947,000
+21.4%
526,322
-15.7%
0.01%
+11.1%
Q3 2022$24,674,000
-10.8%
624,030
-0.8%
0.01%
-10.0%
Q2 2022$27,674,000
+4.7%
628,950
-5.1%
0.01%
+25.0%
Q1 2022$26,425,000
+4.1%
662,638
+5.0%
0.01%
+14.3%
Q4 2021$25,376,000
+6.3%
631,127
+7.6%
0.01%
-12.5%
Q3 2021$23,865,000
-8.1%
586,665
+2.6%
0.01%0.0%
Q2 2021$25,975,000
+4.9%
572,006
-3.7%
0.01%0.0%
Q1 2021$24,772,000
-13.3%
594,212
-11.2%
0.01%
-20.0%
Q4 2020$28,579,000
+148.9%
669,143
+53.2%
0.01%
+100.0%
Q3 2020$11,481,000
-2.4%
436,864
-0.4%
0.01%0.0%
Q2 2020$11,759,000
+59.9%
438,590
+7.3%
0.01%
+25.0%
Q1 2020$7,353,000
+5.2%
408,757
+3.7%
0.00%
+33.3%
Q4 2019$6,990,000
+11.0%
394,239
-2.9%
0.00%0.0%
Q3 2019$6,299,000
-9.8%
406,062
-0.1%
0.00%0.0%
Q2 2019$6,982,000
+74.4%
406,387
+63.4%
0.00%
+50.0%
Q1 2019$4,004,000
+9.2%
248,685
-0.8%
0.00%0.0%
Q4 2018$3,668,000
-12.7%
250,724
+8.5%
0.00%
+100.0%
Q3 2018$4,200,000
+70.0%
231,166
+57.8%
0.00%0.0%
Q2 2018$2,471,000
-13.8%
146,464
+0.1%
0.00%0.0%
Q1 2018$2,867,000
+32.2%
146,367
+36.7%
0.00%0.0%
Q4 2017$2,168,000
-7.6%
107,051
-20.7%
0.00%0.0%
Q3 2017$2,346,000
+34.4%
134,968
-0.8%
0.00%0.0%
Q2 2017$1,745,000
-73.1%
136,072
-72.8%
0.00%
-66.7%
Q1 2017$6,488,000
+22.7%
500,613
-6.4%
0.00%0.0%
Q4 2016$5,286,000
+339.4%
535,003
+670.7%
0.00%
+200.0%
Q4 2015$1,203,000
+43.6%
69,422
+11.3%
0.00%0.0%
Q3 2015$838,000
-73.0%
62,351
-54.7%
0.00%
-50.0%
Q2 2015$3,106,000
+63.4%
137,595
+3.4%
0.00%
+100.0%
Q1 2015$1,901,000
+1745.6%
133,096
+1146.8%
0.00%
Q4 2014$103,000
+186.1%
10,675
+170.6%
0.00%
Q3 2014$36,000
+2.9%
3,945
+12.9%
0.00%
Q2 2014$35,000
-32.7%
3,495
-13.7%
0.00%
Q1 2014$52,000
-14.8%
4,050
-1.5%
0.00%
Q4 2013$61,000
-14.1%
4,110
-36.5%
0.00%
Q3 2013$71,000
+42.0%
6,468
+3.6%
0.00%
Q2 2013$50,0006,2430.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2021
NameSharesValueWeighting ↓
SNYDER CAPITAL MANAGEMENT L P 4,324,232$165,185,6623.73%
Steamboat Capital Partners, LLC 196,898$7,521,5042.79%
2Xideas AG 600,799$22,950,5222.54%
BERNZOTT CAPITAL ADVISORS 171,808$6,563,0662.26%
Redwood Investments, LLC 328,459$12,547,1341.70%
Mesirow Institutional Investment Management, Inc. 380,415$14,531,8531.47%
Granite Investment Partners, LLC 856,253$32,708,8651.37%
Penn Capital Management Company, LLC 324,707$12,453,2111.28%
EFG Asset Management (North America) Corp. 137,739$5,262,3191.25%
First Light Asset Management, LLC 313,536$11,977,0751.14%
View complete list of HALOZYME THERAPEUTICS INC shareholders